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Abstract
Background Due to advances in operative methods and
perioperative care, mortality and morbidity following
major hepatic resection have decreased substantially,
making long-term quality of life (QoL) an increasingly
prominent issue. We evaluated whether postoperative
diagnosis was associated with long-term QoL and health in
patients requiring hepatic surgery for benign or malignant
disease.
Methods QoL was evaluated using the European Orga-
nization for Research and Treatment of Cancer Quality of
Life Questionnaire Core-30 and the liver-specific QLQ-
LMC21 module.
Results Between 2002 and 2006, 249 patients underwent
hepatic surgery for malignant (76%) and benign (24%)
conditions. One hundred thirty-five patients were available
for QoL analysis after a mean of 26.5 months. There was
no statistical difference in global QoL scores between
patients with malignant and benign diseases (p = 0.367).
Neither the extent of the resection (C2 segments vs. \2
segments; p = 0.975; OR = 0.988; 95% CI = 0.461–
2.119) nor patient age had a significant influence on overall
QoL (p = 0.092).
Conclusions These results indicate that long-term QoL
for patients who underwent liver resection for malignant
disease is quite good and that a poor clinical prognosis does
not seem to correlate with a poor QoL.
Introduction
Quality of life (QoL) is a subjective multidimensional
concept that is dynamic over time and encompasses a broad
range of domains, including physical, functional, social,
and emotional well-being [1]. The sum of these compo-
nents does not necessarily equal the subjective assessment
of general overall QoL [1, 2]. For example, there will be
some cancer survivors who report a greater number of
physical problems such as pain, restriction in physical
activities, or sexual dysfunction (i.e., more specific prob-
lems than their healthy counterparts) who nevertheless
report to have relatively good, general, subjective health,
especially with regard to mental health and social and
psychological well-being compared to their matched con-
trols [3, 4]. Care needs to be taken, however, with regard to
these findings and their consequent conclusions, as they
certainly cannot be applied to all cancer patients. For health
professionals and bystanders, there seems to be a discrep-
ancy between reported health-related problems and the
patient’s judgment of his/her overall health status. The
general question, ‘‘on the whole, how would you judge
your health to be,’’ gets answered more positively than
would be expected.
Due to recent advances in operative methods and peri-
operative care, in specialized liver units postoperative
mortality after major hepatic surgery has decreased from
20% to less than 5% and major morbidity has decreased
proportionally. As a result, the indications for and extent of
liver resection (LR) have been dramatically expanded
[5–11]. Age no longer appears to be a contraindication to
major hepatic surgery as recent studies have demonstrated
favorable outcomes, even for elderly patients [12–14]
These facts, combined with increasingly prolonged sur-
vival following LR for hepatocellular carcinoma (HCC),
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cholangiocarcinoma, or colorectal metastases, have con-
tributed to the establishment of new standards [15–20].
What was once considered experimental and extreme now
represents standard procedure in high-volume hepatobiliary
centers [21]. With this reduced morbidity and increased
posthepatectomy survival, QoL has become a leading
issue, as important as disease-free or overall survival [22].
Until now, no studies have addressed the potential dif-
ferences in long-term QoL in patients who have undergone
LR for benign versus malignant conditions. Our aim was to
investigate whether postoperative diagnosis affected long-
term self-estimated QoL and health in these patients.
Materials and methods
This cross-sectional study included 249 consecutive
patients who underwent liver resection for malignant or
benign disease at our Department of Visceral Surgery and
Medicine between January 2002 and June 2006. Exclusion
criteria included death, undergoing only liver biopsy, or an
incomplete medical file. Of the surviving 156 patients, 135
were available for QoL assessment by means of a tele-
phone interview, with the questions and possible answers
being read to them by an independent researcher.
Patients who at the time point of the interview had
undergone LR less than half a year before were excluded
from further analysis in order to avoid early specific
postoperative problems (i.e., surgical complications) con-
founding QoL assessment. There was no limit regarding
the maximum time postsurgery after which a patient was
questioned.
To assess QoL, we used the European Organization for
Research and Treatment of Cancer Quality of Life Ques-
tionnaire Core-30 (EORTC QLQ-C30, version 3.0), which
is a cancer-specific QoL instrument originally used in
cancer clinical trials. It contains five functional scales,
including physical, role, social, emotional, and cognitive
functions, as well as questions specifically aimed at
checking for symptoms often reported by cancer patients
(fatigue, nausea/vomiting, pain, dyspnea, insomnia, loss of
appetite, constipation/diarrhea). The financial impact that
the disease has on the patient is also taken into account.
The questionnaire consists of 30 items of which 28 items
have a 4-point scale and 2 items have a 7-point scale for the
overall QoL and health measure [23].
The QLQ-LMC21 consists of 21 items, each of which
has a 4-point scale. The QLQ-LMC21 was initially devised
to be used for patients with colorectal liver metastases
because the general EORTC QLQ-C30 questionnaire did
not adequately address problems specifically associated
with hepatic metastases. Question categories include items
on food intake, weight loss, pain, jaundice, fatigue, social
problems, anxiety, and the influence of the disease on
sexual activity [24]. Because approximately one-third of
our patients required LR for metastatic colorectal disease,
we used the QLQ-LMC21 questionnaire to better address
hepatobiliary symptoms. Official validation of the QLQ-
LMC21 is still required, although an international valida-
tion study is complete and data analyses are underway. The
provisional scoring system provided by the EORTC (very
similar to the already validated QLQ-C30, version 3.0) was
used in this study.
Ethical considerations
Ethical approval was obtained from the University of Bern
ethical committee (institutional protocol number 18/08).
Written permission was obtained from all study partici-
pants. All eligible patients were given details of the study,
including contact information of the researcher. Patients
were informed about the aim of the study and guaranteed
anonymity and confidentiality with regard to the informa-
tion given to the researcher. A licensing agreement was
obtained from the EORTC for use of QLQ-C30, version 3.0
and the LMC21 questionnaires.
Statistical analysis
All statistical analyses were performed using SAS 9.1 and
R 2.5. The scoring method of the EORTC was applied to
the QLQ-C30 and the QLQ-LMC21 with mandatory re-
coding, summing, and transforming of the 30 and the 21
items, respectively.
For distributional analysis, the v2 test or Fisher’s exact
test was applied for categorical data and the MannWhitney
U test was used for continuous data. Regarding model fit-
ting, the ordinary least-squares criterion was used for linear
regression analysis between two variables, the significance
of which was quantified by analysis of variance (ANOVA).
Estimated odds ratios (OR) and their confidence intervals
(CI) were derived by fitting an ordered logistic regression
model to the data and checking the proportional odds
assumption adequacy with the score test. A two-tailed p
value of less than 0.05 was considered statistically signif-
icant. All statistical analyses were carried out with
professional help from the Institute of Mathematical Sta-
tistics and Actuarial Science, University of Bern, Bern,
Switzerland.
Results
Of the 249 complete patient files, all but 7 patients (2.8%)
could either be tracked down directly or their postoperative
course be accounted for with the help of the family
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physician or the treating oncologist. Of these 242 patients,
86 patients had died in the interim, mostly due to the
underlying disease for which hepatic resection was initially
required. Nine patients died during the initial hospitaliza-
tion. Of these, five died of multiorgan failure, one of liver
failure, two of acute cardiac failure, and one patient died
intraoperatively due to extensive hemorrhage in the setting
of a severe polytrauma. Of the surviving 156 patients, 135
(86.5%) could be contacted by phone for further evalua-
tion. All of these 135 patients consented to answering the
EORTC QoL questionnaire. The mean interval between the
initial surgical intervention and completion of the QoL
questionnaire was 26.5 months (standard deviation
[SD] = 16.2). Patient demographics are summarized in
Table 1.
Table 2 summarizes the indications for hepatic surgery
for all 249 patients, for the 135 patients participating in the
QoL survey, and the 21 surviving patients who could not be
reached for the QoL analysis. Of the initial study popula-
tion, most resections were done for malignant diseases
(n = 189, 76%), and approximately one-quarter of the
patients underwent hepatic surgery for benign diseases
(n = 60, 24%). Of the 135 patients who completed the
QoL questionnaire, 89 patients (66%) suffered from
malignant disease and 46 patients (34%) had benign
disease.
Of the patients who completed the QoL survey, 110
required resection of two or more segments and 25 had
minor resections (less than two complete segments
according to Couinaud) [25]. Most patients had a laparot-
omy and three patients (2.2%) had laparoscopic surgery.
Figure 1 summarizes the extent of the hepatic resections
performed.
Although there was no statistical difference in the
overall self-estimated global QoL and health scores
between patients with malignant and benign diseases
(p = 0.367, Table 3), of the 26 scales and items assessed,
patients with malignant diseases fared significantly worse
in 9 points. In detail, analysis of the EORTC functional
scales (ordered logistic regression) revealed that patients
with malignant diseases fared worse in three of the five
scores, with statistically significant worse results regard-
ing social function (p = 0.014), physical function
(p = 0.007), and role function (p = 0.046). Patients who
required resection for malignant lesions also had worse
symptom scores for fatigue and pain (p = 0.007 and
0.010, respectively). Evaluation of the liver-specific
LMC21 score revealed worse pain scores (p = 0.042),





Alive but not reachedf
(n = 21)
Median age (years) (range) 62 (36–81) 51.5 (19–77) 59 (35-82)*
Gender ratio (male: female) 1.34 (51:38) 0.59 (17:29) 2:1 (14:7)
ASA (I:II:III) 2:46:41 7:27:12 0:11:10
Mean BMI (kg/m2) 23.6 22.9 24.7
Cardiovascular diseasea (%) 35 (39.3) 12 (26.1) 10 (47.6)
Pulmonary diseaseb (%) 17 (19.1) 4 (8.7) 4 (19.0)
Diabetes mellitusc (%) 8 (9.0) 3 (6.5) 1 (4.8)
Chronic renal diseased (%) 3 (3.4) 0 (0.0) 1 (4.8)
Other debilitating comorbiditiese (%) 10 (11.2) 3 (6.5) 5 (23.8)
Number of patients with comorbidities (%) 50 (56.2) 17 (37.0) 15 (71.4)
Median hospital stay in days (range) 13 (7–43) 11 (3–47) 17 (9-37)**
Resection C2 segments (%) 77 (86.5) 33 (71.7) 13 (61.9)
Resection \2 segments (%) 12 (13.5) 13 (28.3) 8 (38.1)
a Cardiovascular disease was defined as the presence of a disorder of the heart or vessels, such as arrhythmia or arterial hypertension, that
required medication, the presence of a pacemaker, cardiac valve disease, coronary heart disease, peripheral arteriosclerosis
b Pulmonary disease was defined as the presence of abnormal lung-function tests and included asthma, COPD
c Diabetes mellitus as defined by the World Health Organization criteria
d Chronic renal disease requiring regular dialysis
e Other comorbidities include severely debilitating diseases resulting in a reduced health status, such as severe depression requiring constant
medication or intermittent in-hospital or ambulatory treatment, severe polyarthritis, advanced stages of Parkinson’s disease
f Statistically significant differences in sociodemographic values are in bold. * p \ 0.05 when comparing the age of patients with benign
diseases to that of patients with malignant diseases and to the 21 patients alive but who had not completed the QoL questionnaire. ** p = 0.019
when comparing median hospital stay of patients with benign diseases to that of the 21 patients alive but who had not completed the QoL
questionnaire. All other intergroup comparisons do not show any significant differences
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increased worries regarding weight loss (p = 0.035), and
more taste problems (p = 0.007) and peripheral neurop-
athy (p = 0.018) for patients with malignant diseases. For
two items in the QLQ-C30 questionnaire (diarrhea,
financial problems) and three items in the LMC21 ques-
tionnaire (fatigue, social relations, and anxiety scale),
there was a tendency toward patients with malignant
diseases having worse scores, although not statistically
significant. Neither the extent of the resection (C2 seg-
ments vs. \2 segments; p = 0.975; OR = 0.988; 95%
CI = 0.461–2.119; Table 3) nor patient age significantly
influenced overall QoL and health (p = 0.092; Fig. 2a).
Subgroup analysis of patients with extended (C2 seg-
ments) versus limited surgery (\2 completed segments)
revealed that patients who underwent extended resection
had a significantly decreased social function score
(p = 0.020), a worse symptom item (constipation,
p \ 0.001), and an impaired eating scale as defined using
the LMC21 questionnaire (p = 0.031). Not surprisingly,
older patients had significantly lower physical and cog-
nitive scores than younger patients (p \ 0.001 and
p = 0.032, respectively; Fig. 2b, c); however, emotional
(p = 0.704), social (p = 0.271), and role function
(p = 0.051) scores were not significantly different.




a All diagnoses were based on
postoperative pathology reports
b Includes the initial study
population of 249 patients
c Includes the subpopulation of
135 patients who completed the
QoL assessment
d Includes the 21 patients who
are known to still be alive but
who could not be reached for
QoL analysis





not reachedd [n (%)]
Metastatic colorectal cancer 77 (30.9) 37 (27.4) 7 (33.3)
Other metastatic disease 40 (16.1) 22 (16.3) 3(14.3)
Neuroendocrine tumor 11 7
Pancreatic cancer 6 1 1
Adrenal gland 5 4
Leiomyosarcoma 3 3
Breast cancer 3 2
Melanoma 3 1
GISTd 2 1 1
Gastric cancer 2 1 1
Uterine cancer 2 1
Teratoma 1 1
Thyroid cancer 1 0
Cholangiocarcinoma 34 (13.7) 15 (11.1) 3 (14.3)
Hepatocellular carcinoma 24 (9.6) 9 (6.7) 3 (14.3)
Other malignancies 14 (5.6) 6 (4.4) 0




Local invasion of gastric cancer,
renal cancer, mesothelioma,
squamous cell carcinoma, GIST
1 each 1 GIST
Trauma 6 (2.4) 4 (3.0) 0
Echinococcus 17 (6.8) 15 (11.1) 1 (4.8)
Benign tumors 37 (14.9) 27 (20) 4 (19)
Cysts 11 9 1
Hemangioma 7 4 1
Focal nodular hyperplasia 6 6
Adenoma 3 1 1
Abscess 2 1
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Discussion
Our data show that patients who underwent LR for
malignant disease fared no worse than their counterparts
with benign disease as far as general, global, self-assessed
QoL and overall self-assessed health were concerned
despite significantly worse results in nine items/scales. Not
unexpectedly, however, patients with malignant diseases
fared worse with regard to physical function scores, spe-
cifically reporting more pain and also having worse social
function scores, suggesting a certain social isolation due to
the underlying disease and the often long therapies
involved.
Similar to our global QoL findings, a recent study
compared health-related QoL for liver cirrhosis patients
with and without HCC [26] and found no difference in QoL
for patients with HCC compared to patients suffering from
cirrhosis alone. This could have been due to the extensive
preoperative information provided to patients that mentally
prepared them for possible malignancy and to the mini-
mally invasive, less-stressful nature of the therapies used
for treating HCC. One might assume that once patients
have come to terms with their diagnosis, their attitude
toward life in general, and with it their self-assessed QoL,
might improve. This is reflected by the fact that the patients
who underwent resection for malignant diseases in our
study population still judge their overall health as being
good despite having more pain, more fatigue, more
symptoms associated with chemo-/radiotherapy (problems
with taste and peripheral neuropathy), and worse social and
role function. There seems to be a certain discrepancy
between the significantly lower subscores, which imply
increased patient discomfort and suffering, and the quite
high global QoL scores. This also contrasts with how
physicians estimate the QoL of the patients they treat. A
study assessing QoL in patients with chemotherapy-resis-
tant colorectal cancer revealed that the scores judged by the
treating physician, using the visual analog scale, were 12%
lower than the patients’ ratings [27]. Other studies,
including palliative-care evaluations, also showed a great
discrepancy between patient-assessed and physician-
assessed QoL [28–30].
The concept of hope, an aspect rarely talked about or
taken into account by physicians, is an important notion
that makes most patients willing to accept toxic chemo-
therapy for minimal benefit in terms of overall survival
[31]. Perez et al. [32] studied patients with metastatic
cancer to determine how many of their patients were
willing to trade survival time in order to gain QoL.
Astonishingly, only 37% of patients were prepared to trade
quantity for quality. The willingness to trade was inde-
pendent of whether the cancer was progressing, the length
of time since the diagnosis of metastatic cancer was made,
age, education, or religious beliefs.
Extended LR (C2 segments) versus limited LR (\2
segments) did not result in a worse overall QoL, although
subset analysis of different symptoms did reveal a reduced
symptom score and more problems with eating for patients
who underwent extended resection. Because most of our
patients had undergone surgery more than two years before
the administration of the QoL questionnaire, it might seem
reasonable to expect similar overall QoL scores regardless
of the extent of the initial surgery. A recent study compared
QoL and return to baseline for patients who underwent
major and minor LR [33] and found, as one might expect,
that there was a quicker return to baseline QoL for patients
who underwent minor surgery. Nevertheless, patients who
needed extensive surgery returned to their individual pre-
operative QoL within 6 months of surgery. Our data fit
nicely with these results, illustrating the need to reassure
Fig. 1 Types of liver resections
performed. A summary is given
of all the liver resections
performed in the 135 patients
taking part in the QoL study.
The patients are divided into
extent of resection (\2
segments vs. C2 segments) and
then into the exact anatomical
resection performed. Lap.
Res. = laparoscopic resection;




seg. = atypical segment
resection; Hemihep.
right = hemihepatectomy right;
Typ. seg. = typical segment
resection
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patients that although initial QoL will deteriorate postop-
eratively, longer-term outcomes are very encouraging.
Indeed, Chen et al. [34] showed that not only did the QoL
of patients who underwent LR for primary liver cancer
recover after surgery, but QoL was better 9 months post-
surgery than before the LR.
Certain aspects of the study design might limit inter-
pretation and merit further discussion. For example, there
is the potential for patients to rate their QoL better than
reality when answering a QoL questionnaire. Self-admin-
istered questionnaires can be a disadvantage to patients
with limited literacy and the information gathered may be
incomplete [35]. Because the ‘‘need to please’’ is likely to
affect all patients similarly, artificial differences within the
subgroup analyses seem unlikely. In adition, because we
did not have a preoperative, pretherapy QoL questionnaire
Table 3 EORTC QLQ-C30 and LMC21 questionnaire - results
Benign Malignant p \2 seg. C2 seg. p
EORCT QLQ-C30
Global health status/QoL 71.7(17.4) 65.4(16.2) 0.367 67.7 67.5 0.975
Functional scalesa
Emotional function 70.8 66.6 0.529 63.6 69.0 0.512
Cognitive function 67.6 68.2 0.927 74.1 66.6 0.299
Social function 78.3 62.7 0.014 82.8 64.6 0.020
Physical function 80.3 61.6 0.007 76.9 66.0 0.201
Role function 76.8 63.5 0.046 71.1 67.3 0.642
Symptom scales/itemsb
Fatigue 55.6 74.4 0.007 62.1 69.4 0.389
Nausea and vomiting 63.9 70.1 0.213 70.2 67.5 0.659
Pain 62.4 78.8 0.010 58.0 70.3 0.114
Dyspnea 64.7 69.7 0.395 64.0 69.0 0.492
Insomnia 65.2 69.5 0.500 71.8 67.1 0.547
Appetite loss 63.4 70.4 0.162 69.7 67.6 0.724
Constipation 71.6 65.4 0.255 62.9 87.5 <0.001
Diarrhea 61.5 71.4 0.085 67.0 68.2 0.862
Financial problems 72.6 65.6 0.085 65.0 68.7 0.458
LMC21
Symptom scalesb
Eating scale 70.8 66.6 0.501 54.5 71.1 0.031
Pain scale 63.3 77.2 0.042 64.6 68.8 0.622
Fatigue scale 59.6 72.4 0.066 58.5 70.2 0.171
Social relations scale 60.0 71.3 0.080 64.0 68.3 0.580
Anxiety scale 59.2 71.7 0.075 66.9 67.7 0.926
Single itemsb
Worry about weight loss 63.0 70.6 0.035 61.5 69.5 0.072
Problems with taste 59.3 71.6 0.007 67.1 67.6 0.936
Dry mouth 62.5 70.0 0.199 61.6 68.8 0.313
Sore mouth/tongue 67.0 68.5 0.750 65.2 68.7 0.531
Peripheral neuropathy 58.0 72.3 0.018 57.7 69.8 0.101
Jaundice 66.4 68.9 0.414 63.5 69.0 0.140
Values are mean ranks (SD of the ranks), p \ 0.05 is considered significant and in bold
a Higher scores indicate better function
b Higher scores indicate more symptoms
The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30, version 3.0) is a
cancer-specific QoL instrument. The QLQ-LMC21 was initially used in patients with colorectal liver metastases. The QLQ-C30 consists of 30
items, of which 28 have a 4-point scale and two have a 7-point scale for the overall QoL and health measure. In analog, the QLQ-LMC21 consists
of 21 items, each item being made up of a 4-point scale. The scoring method of the EORTC was applied with mandatory recoding, summing, and
transforming of the 30 respective 21 items
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with which to compare, it is difficult to deduce which
patients might have had a low baseline QoL that was lar-
gely independent of the liver resection, influenced more by
concomitant diseases or other nonclinical factors. We are
currently conducting a study in which all patients who are
to undergo hepatic surgery are administered the EORTC
QoL questionnaire preoperatively and at defined intervals
postoperatively. This will allow us to compare preoperative
QoL with short-term postoperative QoL, and it will allow
us to follow the evolution of postoperative QoL over time.
Ultimately, these data might enable us to provide more
patient-tailored postoperative follow-up and care in the
future.
Good health is a state of physical, mental, and social
well-being and not merely the absence of disease or infir-
mity. Because a person’s expectations with regard to his/
her health and ability to cope with disabilities and
restrictions can dramatically affect the perception of health
and overall satisfaction with life, two patients with the
same objective health status may have truly different QoLs.
Likewise, patients whose health statuses are objectively
different may rate their QoLs similarly. Healthier patients
are not necessarily happier patients.
Our results demonstrate that irrespective of their
underlying malignant diseases, patients who have under-
gone hepatic resection for primary or secondary
malignancies will judge their overall QoL as being similar
to that of their peers who were treated for benign diseases,
despite faring substantially worse in a significant amount of
subitems according to the two EORTC questionnaires used.
However, care needs to be taken regarding the interpreta-
tion of these global QoL scores, because although patients
with benign disease and patients with malignant disease
may have similar scores, the exact interpretation of these
findings is uncertain and does not automatically imply
equal findings. The global QoL score should therefore not
be interpreted in isolation of the other subscores. Our
results, however, suggest that carefully selected patients
might benefit from more aggressive surgery.
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